Overexpression of cIAP2 contributes to 5-FU resistance and a poor prognosis in oral squamous cell carcinoma

cIAP2 Upregulated by E6 Oncoprotein via Epidermal Growth Factor Receptor/Phosphatidylinositol 3-Kinase/AKT Pathway Confers Resistance to Cisplatin in Human Papillomavirus 16/18-Infected Lung Cancer

(2010) H.-H. Wu et al.   CLINICAL CANCER RESEARCH

Overcoming cancer cell resistance to Smac mimetic induced apoptosis by modulating cIAP-2 expression

(2010) S. L. Petersen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Randomized controlled phase II comparison study of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil versus CCRT with cisplatin, 5-fluorouracil, methotrexate and leucovorin in patients with locally advanced squamous cell carcinoma of the head and neck

(2009) Mamoru Tsukuda et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Down-regulation of cIAP2 enhances 5-FU sensitivity through the apoptotic pathway in human colon cancer cells

(2009) Hideaki Karasawa et al.   CANCER SCIENCE

cIAP2 as a therapeutic target in colorectal cancer and other malignancies

(2009) Koh Miura et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

c-IAP1 and c-IAP2 Are Critical Mediators of Tumor Necrosis Factor α (TNFα)-induced NF-κB Activation

(2008) Eugene Varfolomeev et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Both cIAP1 and cIAP2 regulate TNF -mediated NF- B activation

(2008) D. J. Mahoney et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA